---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-062888"
form_type: "8-K"
ticker: "OKUR"
cik: "0001637715"
company_name: "OnKure Therapeutics, Inc."
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T05:14:09.841884+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Reneo Q3 net loss $19.2M; STRIDE topline results expected December 2023

## Summary
- Net loss of $19.2M ($0.57/sh) vs $13.0M ($0.53/sh) in Q3 2022; R&D expense up to $13.6M.
- Cash, cash equivalents, and short-term investments of $125.6M as of September 30, 2023.
- Topline results from pivotal STRIDE study in adult PMM patients expected in December 2023.
- Repurchased 576,443 shares for $4.4M from vTv Therapeutics in October 2023; shares retired.
- Enrolled 88% of eligible STRIDE patients in open-label extension; 65 patients treated beyond 52 weeks.

## SEC filing metadata
- accession: 0000950170-23-062888
- form_type: 8-K
- ticker: OKUR
- cik: 0001637715
- company_name: OnKure Therapeutics, Inc.
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1637715/000095017023062888/0000950170-23-062888-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1637715/000095017023062888/rphm-20230810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-062888
- JSON: https://secwatch.observer/filing/0000950170-23-062888.json
- Plain text: https://secwatch.observer/filing/0000950170-23-062888.txt

## Key facts
- Earnings Releases
  OnKure Therapeutics, Inc. reported third quarter ended September 30, 2023 results: net income net loss of $19.2 million, or $0.57 per share, EPS $0.57 per share.
  - Period: third quarter ended September 30, 2023
  - Net income: net loss of $19.2 million, or $0.57 per share
  - EPS: $0.57 per share
  - Result: reported results
  source text: Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the third quarter ended September 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1637715/000095017023062888/0000950170-23-062888-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.